Published in Histopathology on June 01, 2003
A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. Case Rep Dermatol (2011) 1.20
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol (2005) 0.88
Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. Case Rep Oncol Med (2015) 0.81
Pemetrexed induced a durable response in heavily pretreated metastatic extramammary Paget's disease. Int J Clin Exp Med (2015) 0.75
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer (1994) 5.52
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer (2009) 2.48
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol (2004) 2.40
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Antibiotic prophylaxis for hysterectomy, a prospective cohort study: cefuroxime, metronidazole, or both? BJOG (2013) 2.00
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol (2006) 1.68
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol (2007) 1.64
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res (2001) 1.60
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59
Surgical management of radiation-associated cutaneous breast angiosarcoma. J Plast Reconstr Aesthet Surg (2011) 1.51
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg (2011) 1.40
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1.38
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst (1992) 1.36
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Effect of age on the survival of breast cancer patients. Eur J Cancer (1997) 1.30
Virtual microscopy. J Clin Pathol (2004) 1.24
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer (1997) 1.14
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol (1998) 1.13
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (1997) 1.10
Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol (1997) 1.10
Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology (1988) 1.08
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.07
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology (1992) 1.03
Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study. Cancer Genet Cytogenet (1997) 1.03
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol (2000) 1.02
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry (1991) 1.02
Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol (1994) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab (1987) 1.01
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer (2000) 1.01
Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol (2006) 1.00
A regression model for identifying patients at high risk of hypotension, bradycardia and nausea during spinal anesthesia. Acta Anaesthesiol Scand (1992) 1.00
Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer (1995) 0.99
The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur J Cancer (1996) 0.99
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. Br J Cancer (1995) 0.98
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol (1997) 0.98
Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer (1996) 0.97
Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol (2000) 0.97
Extracellular matrix proteins of human epidermal keratinocytes and feeder 3T3 cells. J Cell Biol (1982) 0.96
Sequelae in the abdominal wall after pedicled or free TRAM flap surgery. Ann Plast Surg (1996) 0.96
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res (2001) 0.95
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol (2006) 0.94
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol (1992) 0.94
Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer (2000) 0.93
Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol (2007) 0.93
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol (1994) 0.93
Free flap failures. Microsurgery (1995) 0.93
Donor site morbidity of radial forearm flaps. A clinical and ultrasonographic evaluation. Scand J Plast Reconstr Surg Hand Surg (1996) 0.92
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J Clin Pathol (2007) 0.92
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. Cancer Res (1996) 0.92
Bone marrow induced osteogenesis in hydroxyapatite and calcium carbonate implants. Biomaterials (1996) 0.92
Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol (2007) 0.91
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol (2008) 0.91
Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control (2010) 0.91
Analysis of p53 tumor suppressor gene in families with multiple glioma patients. J Neurooncol (2001) 0.90
The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Res Treat (2001) 0.89
New prognostic factors in prostatic carcinoma. Eur Urol (1993) 0.89
12-O-tetradecanoyl phorbol-13-acetate potentiates adenosine 3',5'-monophosphate-mediated chorionic gonadotropin secretion by cultured human choriocarcinoma cells. Endocrinology (1987) 0.89
Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol (1995) 0.89
Free flap reconstructions of tibial fractures complicated after internal fixation. J Trauma (1995) 0.88
Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol (1997) 0.88
Mechanical loading regulates tenascin-C expression in the osteotendinous junction. J Cell Sci (1999) 0.88
The visibility of cancer on earlier mammograms in a population-based screening programme. Eur J Cancer (1999) 0.88
Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol (2011) 0.87
Thermographic mapping of perforators and skin blood flow in the free transverse rectus abdominis musculocutaneous flap. Ann Plast Surg (1995) 0.87
Blood flow in a pedal bypass combined with a free muscle flap. Eur J Vasc Endovasc Surg (2001) 0.87
Haemostatic disturbances in burned patients during early excision and skin grafting. Blood Coagul Fibrinolysis (1998) 0.87
Problems in wearing external prosthesis after mastectomy and patient's desire for breast reconstruction. Ann Chir Gynaecol (1998) 0.86
Expression of cyclooxygenase-2 and prostanoid receptors by human myometrium. J Clin Endocrinol Metab (2000) 0.85
Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology (2002) 0.85